|

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

RECRUITINGN/ASponsored by Seoul National University Hospital
Actively Recruiting
PhaseN/A
SponsorSeoul National University Hospital
Started2025-05-21
Est. completion2027-05-31
Eligibility
Age19 Years+
SexFEMALE
Healthy vol.Accepted

Summary

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.

Eligibility

Age: 19 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies.
* Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin.
* Patients who are able to read and voluntarily provide written informed consent.
* Aged 19 years or older.

Exclusion Criteria:

* Patients who do not wish to participate in this study voluntarily.
* Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.

Conditions4

CancerCervical CancerEndometrial CancerOvarian Cancer

Interventions4

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.